On the evening of March 2nd, AideaPharmaceutical...The company announced that it plans to raise no more than RMB 1.277 billion through a private placement of shares. The funds will be invested in three main areas: RMB 767 million for the global clinical development of a novel HIV integrase inhibitor; RMB 130 million for the acquisition of a 22.23% minority stake in Nanda Pharmaceutical; and RMB 380 million to supplement working capital. Fu Heliang, one of the company's actual controllers and chairman, plans to subscribe for RMB 30 million to RMB 50 million of the issued shares.

AideaPharmaceuticals , as an innovative anti-HIV drug manufacturer in ChinaAs a leading company, it has already launched two Class 1 innovative drugs in China : Enovilin and Enovitil. Currently, integrase inhibitors have become one of the mainstream treatment options for HIV/AIDS globally. In China, there are currently no independently developed innovative HIV integrase inhibitors on the market. AideaPharmaceuticals' novel integrase inhibitor ACC017 is currently undergoing Phase III clinical trials. The company plans to initiate a multi-center clinical study in China of ADC118, a triple combination therapy based on ACC017, with the ultimate goal of obtaining approval for marketing and commercialization in China.

Regarding its overseas expansion, the company plans to focus on the US market by launching an "international multi-center clinical research project" to complete the Phase III clinical trials of this type of drug in the US. The core objective is to successfully submit an NDA (New Drug Application) and obtain approval for market launch, thereby further expanding its overseas market.

Human-derived protein business is the company's key second growth driver. Nanda Pharmaceutical, as a domestic manufacturer of urokinase raw materials...A leading integrated enterprise in pharmaceutical preparations, whose core product, injectable urokinase preparations, has consistently held a dominant position in domestic hospitals for many years.With the highest market share in the terminal market, it has become an important pillar of the company's performance.

AideaPharmaceuticals has submitted applications for two Class 2 new drugs and received clinical trial approvals, focusing on building an innovative pipeline in the fields of anti-inflammation and stroke. The company plans to invest 130 million yuan to acquire a 22.23% minority stake in Nanda Pharmaceuticals. After the acquisition, Aidi's controlling stake in Nanda Pharmaceuticals will further increase to 73.36%, allowing for more comprehensive integration of both companies' R&D, production, and sales resources, deepening its "integrated human protein raw material and formulation" strategy, and continuously releasing new growth momentum.

https://finance.eastmoney.com/a/202603033659998242.html